-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AIV-007 in Diabetic Macular Edema
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AIV-007 in Diabetic Macular Edema report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AIV-007 in Diabetic Macular Edema Drug Details: AIV-007 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AIV-007 in Wet (Neovascular / Exudative) Macular Degeneration
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AIV-007 in Wet (Neovascular / Exudative) Macular Degeneration report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AIV-007 in Wet (Neovascular / Exudative) Macular...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AIV001-C01 in Basal Cell Carcinoma (Basal Cell Epithelioma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AIV001-C01 in Basal Cell Carcinoma (Basal Cell Epithelioma) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AIV001-C01 in Basal Cell Carcinoma (Basal Cell Epithelioma)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AIV001-C01 in Nonmelanomatous Skin Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AIV001-C01 in Nonmelanomatous Skin Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AIV001-C01 in Nonmelanomatous Skin Cancer Drug Details: AIV-001 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AIV-001 in Basal Cell Carcinoma (Basal Cell Epithelioma)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. AIV-001 in Basal Cell Carcinoma (Basal Cell Epithelioma) Drug Details: AIV-001 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AIV-001 in Nonmelanomatous Skin Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. AIV-001 in Nonmelanomatous Skin Cancer Drug Details: AIV-001 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Subasumstat in Metastatic Colorectal Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Subasumstat in Metastatic Colorectal Cancer Drug Details: TAK-981 is under development for the treatment of...
-
Product Insights
NewBenign Prostatic Hyperplasia – Drugs In Development, 2024
Empower your strategies with our Benign Prostatic Hyperplasia – Drugs In Development, 2024 report and make more profitable business decisions. Benign prostatic hyperplasia (BPH) is a non-cancerous enlargement of the prostate, a small gland that encircles the urethra in males and produces a fluid that makes up part of semen. Symptoms include decreased strength of the urine stream, dribbling after urination, pain during urination, waking at night to urinate, and difficulty starting a urine stream. Treatment options for BPH include surgery...
-
Product Insights
NewBasal Cell Carcinoma (Basal Cell Epithelioma) – Drugs In Development, 2024
Empower your strategies with our Basal Cell Carcinoma (Basal Cell Epithelioma) – Drugs In Development, 2024 report and make more profitable business decisions. Basal cell carcinoma is a type of skin cancer which begins in the basal cells. Symptoms include a waxy bump; a scaly, brown, or flesh-colored patch; or a white, waxy scar. Predisposing factors include age, family history, and exposure to radiation and immunosuppressant medications. Treatment includes chemotherapy and surgery. The Basal Cell Carcinoma (Basal Cell Epithelioma) drugs in...
-
Product Insights
NewNonmelanomatous Skin Cancer – Drugs In Development, 2024
Empower your strategies with our Nonmelanomatous Skin Cancer – Drugs In Development, 2024 report and make more profitable business decisions. Nonmelanoma skin cancer comprises basal cell carcinoma (BCC) and squamous cell carcinoma (SCC), originating from skin cells other than melanocytes. Linked to sun exposure, these cancers often appear on sun-exposed areas. BCC, the most prevalent, usually presents as a pearly bump or a sore that doesn't heal. SCC may appear as a scaly patch or a firm, red nodule. While rarely...